Dr. David Christopher Fisher, MD

Dr. Fisher practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Fisher's NPI, 1770542391, was assigned on March 22, 2006. Dr. Fisher graduated from University of Massachusetts Medical School in 1989. Dr. Fisher holds Massachusetts license 80650.

Dr. Fisher's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Fisher's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Fisher is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Fisher to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fisher practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Fisher's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Fisher is licensed in Massachusetts.

CMS data shows 911 Medicare services from Dr. Fisher across 8 procedure codes in 2024, for 470 Medicare patients. Medicare paid $66,300 for them.

CMS counts 470 Medicare patients who saw Dr. Fisher in 2024. The largest group is 65 to 74, with 229 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fisher's median patient age at 71, with 44% women.

In 2024, Dr. Fisher wrote 483 Medicare Part D claims for 113 patients. 57% of them were for generic drugs. CMS names the drug for 312 of them, across 11 drugs with 11 or more claims each, at $2,646,225 in total drug cost. In 2023, CMS named 407 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Fisher for performance year 2024, reported as part of a group. Dr. Fisher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fisher as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 116 papers to Dr. Fisher, published from 2011 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation and Transplantation, Autologous. Dr. Fisher has published most often in Leuk Lymphoma. Dr. Fisher's most frequent co-authors are Philippe Armand, MD, PhD, Eric David Jacobsen, MD and Caron Alyce Jacobson, MD.

Dmand AI links Dr. Fisher to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Lymphoma, T-Cell, Cutaneous, Liposarcoma, Myxoid and Lymphoma, Large-Cell, Anaplastic.

CMS Open Payments shows 75 general payments to Dr. Fisher from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Kyowa Kirin, Inc. paid the most, $20,695. It also lists 1 research payment totaling $1,404 in 2017.

Dr. Fisher graduated from University of Massachusetts Medical School in 1989.